{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:31:10Z","timestamp":1759530670697,"version":"3.41.2"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Recepta Biopharma, S\u00e3o Paulo, Brazil"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1136\/ijgc-2020-002239","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T13:41:27Z","timestamp":1614951687000},"page":"562-568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission"],"prefix":"10.1016","volume":"31","clinical-trial-number":[{"clinical-trial-number":"nct01137071","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01137071","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2788-2616","authenticated-orcid":false,"given":"Oren","family":"Smaletz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Ismael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3176-9747","authenticated-orcid":false,"given":"Maria","family":"Del Pilar Estevez-Diz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana L O","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0991-1217","authenticated-orcid":false,"given":"Ana Luiza Gomes","family":"de Morais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1602-7745","authenticated-orcid":false,"given":"Geraldo Fel\u00edcio","family":"Cunha-Junior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio J","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venancio A","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0650-7764","authenticated-orcid":false,"given":"Ana Maria","family":"Moro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda P","family":"Yeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Lopes","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indrani","family":"Majumder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric W","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2020-002239_bb0010","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1200\/JCO.2002.20.5.1238","article-title":"Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer","volume":"20","author":"Dizon","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-002239_bb0015","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-002239_bb0020","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2020-002239_bb0025","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2020-002239_bb0030","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/(SICI)1097-0215(19960208)65:4<406::AID-IJC2>3.0.CO;2-0","article-title":"Serological and immunochemical analysis of Lewis-Y (Ley) blood group antigen expression in epithelial ovarian cancer","volume":"65","author":"Yin","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1136\/ijgc-2020-002239_bb0035","doi-asserted-by":"crossref","first-page":"12957","DOI":"10.1073\/pnas.91.26.12957","article-title":"Specificity analysis of blood group Lewis-Y (Le(y)) antibodies generatedagainst synthetic and natural Le(y) determinants","volume":"91","author":"Kitamura","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/ijgc-2020-002239_bb0040","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ygyno.2015.05.023","article-title":"A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant\/refractory ovarian, fallopian tube and primary peritoneal carcinoma","volume":"138","author":"Smaletz","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002239_bb0045","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 . Available: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference:8.5x11.pdf"},{"key":"10.1136\/ijgc-2020-002239_bb0050","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2020-002239_bb0055","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1158\/1078-0432.CCR-07-0284","article-title":"A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen","volume":"13","author":"Scott","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2020-002239_bb0060","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/JTO.0b013e3181560dcc","article-title":"Targeting Lewis-Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels","volume":"2","author":"Krug","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1136\/ijgc-2020-002239_bb0065","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ygyno.2007.05.008","article-title":"Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials","volume":"106","author":"Harrison","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002239_bb0070","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-002239_bb0075","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2020-002239_bb0080","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.6002","article-title":"Final overall survival (OS) results from SOLO2\/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (PTS) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation","volume":"38","author":"Poveda","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-002239_bb0085","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002239_bb0090","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.1997.15.4.1309","article-title":"High-dose chemotherapy with autologous transplantation for persistent\/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients","volume":"15","author":"Stiff","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-002239_bb0095","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2019.09.015","volume":"155","author":"O'Cearbhaill","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002239_bb0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.6000","article-title":"Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of ago desktop III\/ENGOT-ov20","volume":"38","author":"Du Bois","year":"2020","journal-title":"JCO"},{"key":"10.1136\/ijgc-2020-002239_bb0105","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med Overseas Ed"},{"key":"10.1136\/ijgc-2020-002239_bb0110","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2020-002239_bb0115","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ygyno.2019.12.033","article-title":"Low-grade serous ovarian cancer: state of the science","volume":"156","author":"Slomovitz","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002239_bb0120","first-page":"919","article-title":"Lewis blood group-related antigen expression in normal gastric epithelium, intestinal metaplasia, gastric adenoma, and gastric carcinoma","volume":"88","author":"Kobayashi","year":"1993","journal-title":"Am J Gastroenterol"},{"key":"10.1136\/ijgc-2020-002239_bb0125","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1200\/EDBK_280539","article-title":"Immune therapy opportunities in ovarian cancer","volume":"40","author":"Kandalaft","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24023065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24023065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2020-002239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:26:31Z","timestamp":1753233991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24023065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1048891X24023065"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2020-002239","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2020-002239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}